NasdaqGS:DFTXPharmaceuticals
Definium Therapeutics (DFTX) Posts Another Positive Phase 3, Is The Stock Still A Bargain?
Definium Therapeutics (DFTX) has become a talking point after its Phase 3 Panorama trial of DT120 ODT for generalized anxiety disorder met primary and key secondary endpoints, with management highlighting both efficacy and tolerability.
The Phase 3 Panorama result lands after a sharp run in Definium Therapeutics’ share price this year, with the stock at US$38.81 and a year to date share price return of 184.53%, while the 1 year total shareholder return of 329.31% and 3 year total shareholder...